OPKO Health第一季度每股亏损为$0.01，超出预期，营收下降至$182.2M。 OPKO Health Q1 loss per share of $0.01, beating estimates, while revenue decreased to $182.2M.

生物技术公司OPKO Health报告了第一季度每股亏损0.01美元,超过分析师估计的0.09美元,而收入则从上一年的1.84亿美元下降到1.82亿美元. Biotech firm OPKO Health reported a Q1 loss per share of $0.01, beating analyst estimates of $0.09, while revenue was down to $182.2M from $184.7M in the previous year. 该公司的市场上限为1.05B美元,PE比率为-4.29。 The company has a market cap of $1.05B and a PE ratio of -4.29. 内幕人士一直在卖股票, 分析师意见各异, 有些认为OPKO健康是“买”的, Insiders have been selling stock, and analysts have varied opinions, with some rating OPKO Health a "buy" and others a "sell." OPKO 保健在美国和国际上的诊断和制药企业中运作。 OPKO Health operates in diagnostics and pharmaceuticals businesses in the US and internationally.